EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Analysis of Single-cell and Bulk-RNA Sequencing Data to Identify Redox-related Genes as Prognostic Biomarkers and Therapeutic Targets of Lung Adenocarcinoma With Osimertinib Resistance

Chen Fang, Chaoxing Liu, Rong Qi, Jiabin Ding, Ting Luo, Feng Yu, Guohua Zhang, Chao Shi, Daya Luo, Feng Qiu

Frontiers in Bioscience-Landmark · 25.09.2025 · 30 (9)

DOI: 10.31083/fbl40454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 25.09.2025. Verfasst von Chen Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, 330000 Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Tyrosine Kinase Inhibitors, Antineoplastic Agents, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Surface project of the Natural Science Foundation of Jiangxi Province, Technology Supporting Program of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acquired resistance limits the therapeutic efficacy of osimertinib in lung adenocarcinoma (LUAD). Redox homeostasis is crucial for LUAD progression. However, how redox imbalance interacts with the tumor microenvironment (TME) to drive osimertinib resistance (OR) remains unclear.

Methods

The single-cell RNA sequencing (scRNA-seq) data GSE243562 were combined with the Cancer Genome Atlas (TCGA)-LUAD transcriptomes to map the TME cell population heterogeneity in osimertinib-resistant LUAD. Through univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regularization, a prognostic signature founded on redox-related genes (RRGs) was built. Therapeutic compounds targeting these signature genes were prioritized by molecular docking. Their expression patterns were subsequently validated in vitro.

Results

Cancer-associated fibroblasts (CAFs) were central hubs in the TME of osimertinib-resistant LUAD, exhibiting enhanced intercellular communication. Computational profiling identified 10 differentially expressed RRGs, predominantly enriched in CAFs. Using a six-gene signature comprising AGER, CYP2J2, FMO2, HSPA1B, SOD3, and VASN, we categorized LUAD patients into separate risk categories. High-risk patients showed significantly reduced survival, an immunosuppressive status, and a higher tumor mutation burden (p < 0.05). The overexpression of these six genes was confirmed in OR cells. Critically, inhibiting SOD3 restored osimertinib sensitivity in vitro (p < 0.05). Clinically, SOD3 expression was lower in patients sensitive to third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) than in those with resistant disease.

Conclusions

Targeting CAFs represents a promising strategy to overcome osimertinib resistance. Our six-gene redox signature offers a clinical framework for patient risk stratification and novel therapeutic strategy design. Future work will explore these targets to develop new treatments for LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungTyrosine Kinase InhibitorsAntineoplastic AgentsBiomarkers, TumorLung NeoplasmsCarcinoma, Non-Small-Cell LungSingle-Cell Gene Expression AnalysisSequence Analysis, RNAGene Expression Regulation, NeoplasticDrug Resistance, NeoplasmOxidation-ReductionAcrylamidesAniline CompoundsIndolesPyrimidinesPrognosisCancer-Associated FibroblastsCell CommunicationTumor MicroenvironmentMolecular Docking SimulationCell Line, TumorKaplan-Meier EstimateHumans

Stichwörter der Autor:innen

biomarkerslung adenocarcinomaosimertiniboxidative stresssingle-cell analysistranscriptome

Substanzen

osimertinibTyrosine Kinase InhibitorsAntineoplastic AgentsAcrylamidesAniline CompoundsIndolesPyrimidinesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, 330000 Nanchang, Jiangxi, China.
  • Nanchang Key Laboratory of Tumor Gene Diagnosis and Innovative Treatment Research, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, 330000 Nanchang, Jiangxi, China.
  • Department of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, 330000 Nanchang, Jiangxi, China.
  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, 330006 Nanchang, Jiangxi, China.

Förderung

  • National Natural Science Foundation of China
  • Surface project of the Natural Science Foundation of Jiangxi Province
  • Technology Supporting Program of Jiangxi Province
  • Major science and technology research projects of Nanchang

Zitieren

APA

Fang, C., Liu, C., Qi, R., Ding, J., Luo, T., Yu, F., Zhang, G., Shi, C., Luo, D., & Qiu, F. (2025). Integrated Analysis of Single-cell and Bulk-RNA Sequencing Data to Identify Redox-related Genes as Prognostic Biomarkers and Therapeutic Targets of Lung Adenocarcinoma With Osimertinib Resistance. Frontiers in Bioscience-Landmark, 30(9). https://doi.org/10.31083/fbl40454

Vancouver

Fang C, Liu C, Qi R, Ding J, Luo T, Yu F, et al. Integrated Analysis of Single-cell and Bulk-RNA Sequencing Data to Identify Redox-related Genes as Prognostic Biomarkers and Therapeutic Targets of Lung Adenocarcinoma With Osimertinib Resistance. Frontiers in Bioscience-Landmark. 2025;30(9). doi:10.31083/fbl40454

BibTeX
@article{Fang2025,
  author = {Fang, Chen and Liu, Chaoxing and Qi, Rong and Ding, Jiabin and Luo, Ting and Yu, Feng and Zhang, Guohua and Shi, Chao and Luo, Daya and Qiu, Feng},
  title = {Integrated Analysis of Single-cell and Bulk-RNA Sequencing Data to Identify Redox-related Genes as Prognostic Biomarkers and Therapeutic Targets of Lung Adenocarcinoma With Osimertinib Resistance},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  volume = {30},
  number = {9},
  doi = {10.31083/fbl40454}
}
Kostenlos starten →